SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: erickerickson who wrote (62844)9/27/2024 12:41:55 PM
From: scorman13 Recommendations

Recommended By
erickerickson
erippetoe
jhcimmu

  Read Replies (2) of 63324
 
Erick, you are confusing a possible cherry picking on the original 64patient 28day placebo controlled trial, with the OL extention, CMS, then continuation, which provide a 2yr zero cogs loss vs 11% decline from 20+yr historic placebo degradation... that is a fact! QED.

Odd that you bailed, while Matt N, who has a personal family medical risk, has increased his position to 5% of the outstanding shares, and who has spoken to Wang, Remi, Rick, and Lindsay and does NOT have the concerns you expressed.

OT... who gets the $40mill anyway?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News